alemtuzumab

基本解释

Two alemtuzumab and three Thymoglobulin patients suffered rejection episodes.
阿仑单抗组有2例而抗胸腺细胞球蛋白组有3例发生排斥反应.
Alemtuzumab is an immunosuppressive antibody that depletes normal T-cells as well as B-cells.
阿仑单抗是一种针对T、B细胞的单克隆抗体。
BACKGROUND.: An increase in the incidence of autoimmune diseases has been described in patients receiing alemtuzumab.
背景：接受阿仑单抗免疫诱导治疗治疗患者的自身免疫性疾病发生率增加。
One-year cumulatie graft surial was 85.7% for the alemtuzumab group and 87.5% for the Thymoglobulin group.
1年累积生存率阿仑单抗组为85.;7%25;抗胸腺细胞球蛋白组为87
Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单抗;一种人源性抗-CD52抗体;在免疫耐受诱导方案中效果显著;需要最少的免疫抑制维持药物.